Program
Famotidine
Also written as “Atazanavir+Ritonavir+Tenofovir+Famotidine”, “Famotidine Tablets, 40 mg” and “Atazanavir/Ritonavir + Famotidine”.
Its studies are mostly in COVID-19 · HIV Infections · Ulcer · Arthritis, Juvenile · Heartburn, led by 8 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Leidos Life Sciences | 30 open or running | phase 2since Oct 7, 2021 | Oct 7, 2021 | none ahead |
| Amgen | 20 open or running | phase 4since Mar 20, 2012 | Mar 19, 2007 | none ahead |
| Perrigo | 20 open or running | phase 1since Dec 3, 2008 | Dec 3, 2008 | none ahead |
| Sun Pharmaceutical Industries | 20 open or running | no phasesince Feb 18, 2010 | Feb 18, 2010 | none ahead |
| Astellas Pharma | 10 open or running | phase 3since Sep 1, 2005 | Sep 1, 2005 | none ahead |
| Dr. Reddy's Laboratories | 10 open or running | phase 1since Jan 12, 2012 | Jan 12, 2012 | none ahead |
| drpykessupplements.com | 10 open or running | phase 4since Sep 21, 2020 | Sep 21, 2020 | none ahead |
| Pfizer | 10 open or running | phase 1since Mar 24, 2014 | Mar 24, 2014 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 1, 2005First study: phase 3 study in Gastroesophageal RefluxNew to Astellas PharmaAstellas Pharma · NCT00141960 · 480 enrolled · Japan
- Mar 19, 2007Amgen's first study: phase 3 study in UlcerNew to AmgenAmgen · NCT00450216 · 906 enrolled
- Dec 3, 2008Perrigo's first studies: 2 phase 1 studies in BioavailabilityNew to PerrigoPerrigo · NCT00803192, NCT00802828
- Feb 18, 2010Sun Pharmaceutical Industries's first studies: 2 no phase studies in HealthyNew to Sun Pharmaceutical IndustriesSun Pharmaceutical Industries · NCT01079065, NCT01079052
- Jan 12, 2012Dr. Reddy's Laboratories's first study: phase 1 study in HealthyNew to Dr. Reddy's LaboratoriesDr. Reddy's Laboratories · NCT01511731 · 30 enrolled · Canada
- Mar 20, 2012Phase 4 study in Arthritis, JuvenileAmgen · NCT01563185 · 12 enrolled · United States
- Mar 24, 2014Pfizer's first study: phase 1 study in HealthyNew to PfizerPfizer · NCT02097329 · 27 enrolled · United States
- Sep 21, 2020drpykessupplements.com's first study: phase 4 study in COVID-19New to drpykessupplements.comdrpykessupplements.com · NCT04565392 · United States
- Oct 7, 2021Leidos Life Sciences's first studies: 3 phase 2 studies in COVID-19New to Leidos Life SciencesLeidos Life Sciences · NCT05085574, NCT05077969, NCT05077332
TargetBeta
“Histamine H2 receptor antagonist”ChEMBL 37, by rule
Studies
All 13 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT05085574COVID-19 | 2 | Withdrawn | Leidos Life Sciences | Feb 7, 2023 | 0 |
| NCT05077969COVID-19 · United States | 2 | Terminated | Leidos Life Sciences | Jun 28, 2022 | 4 |
| NCT05077332COVID-19 · United States | 2 | Completed | Leidos Life Sciences | Nov 10, 2025 | 4 |
| NCT04565392COVID-19 · United States | 4 | Withdrawn | drpykessupplements.com | Nov 1, 2021 | 0 |
| NCT02097329Healthy · United States | 1 | Completed | Pfizer | Jun 2014 | 27 |
| NCT01563185Arthritis, Juvenile · United States | 4 | Completed | Amgen | Mar 2015 | 12 |
| NCT01511731Healthy · Canada | 1 | Completed | Dr. Reddy's Laboratories | Oct 1998 | 30 |
| NCT01079065Healthy · India | – | Completed | Sun Pharmaceutical Industries | Nov 2007 | 32 |
| NCT01079052Healthy · India | – | Completed | Sun Pharmaceutical Industries | Nov 2007 | 24 |
| NCT00803192Bioavailability | 1 | Completed | Perrigo | Jun 2004 | 44 |
| NCT00802828Bioavailability | 1 | Completed | Perrigo | Jun 2004 | 44 |
| NCT00450216Ulcer | 3 | Completed | Amgen | Aug 2008 | 906 |
| NCT00141960Gastroesophageal Reflux · Japan | 3 | Completed | Astellas Pharma | 480 |
How it is read
Names in the registry
- “Famotidine”, 8 entries
- “Atazanavir+Ritonavir+Tenofovir+Famotidine”, 4 entries
- “Famotidine Tablets, 40 mg”, 2 entries
- “Atazanavir/Ritonavir + Famotidine”, 2 entries
- “Nirogacestat and Famotidine”, 1 entry
Conditions, from the studies’ own filings
- COVID-19, 4 studies
- HIV Infections, 2 studies
- Ulcer, 1 study
- Arthritis, Juvenile, 1 study
- Heartburn, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.